Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance ...

At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to ...

Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1 Remibrutinib, a highly selective oral BTK inhibitor, was ...

Welcome to the Novartis US Privacy Policy Center. Novartis Pharmaceuticals Corporation (“Novartis”, “we”, “our”, or “us”) is a United States-based ...

Sie suchen Kreativität und Innovation? Novartis bietet Ihnen das nötige Umfeld! Menschen, die uns mit ihrem Können und ihrer Erfahrung weiterbringen, können das Gleiche auch von uns erwarten. Think ...

Coartem Baby was developed by Novartis with the scientific and financial support of MMV, and as part of the PAMAfrica ...

Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 32 of the Condensed Interim Financial Report. Unless otherwise ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Novartis anuncia los resultados financieros del cuarto trimestre y del año completo 2024 de la compañía. Informe Integrado Novartis en la Sociedad 2024 Lee más sobre nuestro desempeño en relación con ...

April 26, 2023 Today Novartis has published updated 2022 quarterly and full year segment financials reflecting transfers of Sandoz biotechnology manufacturing services to other companies’ activities ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

We provide a variety of access options for Novartis medicines so they can be accessed by as many patients as easily as possible. Novartis works closely with healthcare professionals around the world ...